Advocacy Campaigns

CCA works to advocate for the IBD community in a range of ways:

  • Lobbying governments for funding
  • Providing submissions about health policy
  • Raising consumer needs to researchers and industry
  • Awareness campaigns

Current advocacy campaigns

nurse with mask

Help improve the quality of life for regional Australians living with chronic inflammatory conditions

Closed 2022

Review of the National Medicines Policy

Closed October 2021.

Have your say on PBS listings for IBD Medications

The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on vedolizumab (Entyvio®) for pouchitis, another adalimumab biosimilar (Hyrimoz®) or methotrexate (Methoblastin®) then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 27 May 2024.

Drug Name, form(s), strength(s) and Sponsor, Submission type
(Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing)
Drug Type and Use
(What is the drug used to treat?)
Listing requested by Sponsor / Purpose of Submission
(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.)

Injection 20 mg in 0.2 mL pre-filled syringe
Injection 40 mg in 0.4 mL pre-filled syringe
Injection 40 mg in 0.4 mL pre-filled pen
Injection 80 mg 0.8 mL pre-filled syringe
Injection 80 mg in 0.8 mL pre-filled pen



(New PBS listing)
Severe Crohn disease (CD)
Moderate to severe ulcerative colitis (UC)
Severe active juvenile idiopathic arthritis (JIA)
Complex refractory fistulising Crohn disease (CD)
Severe active rheumatoid arthritis (RA)
Severe psoriatic arthritis (PsA)
Ankylosing spondylitis (AS)
Severe chronic plaque psoriasis (CPP)
Moderate to severe hidradenitis suppurativa (HS)
To request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listings for initial treatment and Authority Required (STREAMLINED) listings for subsequent continuing treatment of new forms of an existing biosimilar under the same conditions as the currently listed forms and strengths as its reference biologic.

Tablet 2.5 mg (as sodium)
Tablet 10 mg (as sodium)



(New PBS listing)
Chemotherapy and inflammatory conditionsTo request a General Schedule unrestricted listing of new forms and to request listing of a new pack size.

Powder for injection 300 mg



(Change to existing listing)
Chronic pouchitisTo request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for initial treatment and an Authority Required (Telephone/Online) listing for continuing treatment of chronic pouchitis.

For information about the PBS meeting visit the PBAC meeting page on the PBS website.